

# ICD-10 Procedure Coding System (ICD-10-PCS) 2021 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

# 00H

|           |  |  |   |                       |
|-----------|--|--|---|-----------------------|
| No change | <i>Section</i>   | <b>0</b>   | Medical and Surgical  |                       |
|           | <i>Body System</i>   | <b>0</b>   | Central Nervous System and Cranial Nerves   |                       |
|           | <i>Operation</i>   | <b>H</b>   | Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part                                  |                       |
| Heading   | <i>Body Part</i>   | <i>Approach</i>  | <i>Device</i>   | <i>Qualifier</i>      |
| FY2021    | <b>0</b> Brain   | <b>0</b> Open  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>4</b> Radioactive Element, Cesium-131 Collagen Implant<br><b>M</b> Neurostimulator Lead<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| FY2021    | <b>0</b> Brain   | <b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic                  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>M</b> Neurostimulator Lead<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |
| FY2021    | <b>6</b> Cerebral Ventricle<br><b>E</b> Cranial Nerve<br><b>U</b> Spinal Canal<br><b>V</b> Spinal Cord | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>M</b> Neurostimulator Lead<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |

## 01H

|           |                           |          |  |  |
|-----------|---------------------------|----------|--|--|
| No change | <i>Section</i>            | <b>0</b> | Medical and Surgical   |  |
|           | <i>Body System</i>        | <b>1</b> | Peripheral Nervous System  |  |
|           | <i>Operation</i>          | <b>H</b> | Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |  |
| Heading   | <i>Body Part</i>          |          | <i>Approach</i>  | <i>Device</i>  |
| FY2021    | <b>Y</b> Peripheral Nerve |          | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>M</b> Neurostimulator Lead<br><b>Y</b> Other Device |
|           |                           |          |  | <b>Z</b> No Qualifier  |

021

|           |   |   |   |  |
|-----------|---|---|---|--|
| No change | <b>Section 0</b> Medical and Surgical   |   |   |  |
|           | <b>Body System 2</b> Heart and Great Vessels  |   |   |  |
|           | <b>Operation 1</b> Bypass: Altering the route of passage of the contents of a tubular body part   |   |   |  |
| Heading   | <b>Body Part</b>  | <b>Approach</b>                                   | <b>Device</b>   | <b>Qualifier</b>   |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries | <b>0</b> Open                                     | <b>8</b> Zooplastic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute | <b>3</b> Coronary Artery<br><b>8</b> Internal Mammary, Right<br><b>9</b> Internal Mammary, Left<br><b>C</b> Thoracic Artery<br><b>F</b> Abdominal Artery<br><b>W</b> Aorta |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries | <b>0</b> Open                                     | <b>Z</b> No Device  | <b>3</b> Coronary Artery<br><b>8</b> Internal Mammary, Right<br><b>9</b> Internal Mammary, Left<br><b>C</b> Thoracic Artery<br><b>F</b> Abdominal Artery                   |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries | <b>3</b> Percutaneous                             | <b>4</b> Intraluminal Device, Drug-eluting<br><b>D</b> Intraluminal Device  | <b>4</b> Coronary Vein   |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries | <b>4</b> Percutaneous Endoscopic                  | <b>4</b> Intraluminal Device, Drug-eluting<br><b>D</b> Intraluminal Device  | <b>4</b> Coronary Vein   |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries | <b>4</b> Percutaneous Endoscopic                  | <b>8</b> Zooplastic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute | <b>3</b> Coronary Artery<br><b>8</b> Internal Mammary, Right<br><b>9</b> Internal Mammary, Left<br><b>C</b> Thoracic Artery<br><b>F</b> Abdominal Artery<br><b>W</b> Aorta |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries | <b>4</b> Percutaneous Endoscopic                  | <b>Z</b> No Device  | <b>3</b> Coronary Artery<br><b>8</b> Internal Mammary, Right<br><b>9</b> Internal Mammary, Left<br><b>C</b> Thoracic Artery<br><b>F</b> Abdominal Artery                   |
| No change | <b>6</b> Atrium, Right  | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>8</b> Zooplastic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute | <b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left  |

|           |   |   |  |  |
|-----------|---|---|--|--|
| No change | <b>6</b> Atrium, Right  | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>Z</b> No Device   | <b>7</b> Atrium, Left<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left   |
| No change | <b>6</b> Atrium, Right  | <b>3</b> Percutaneous                             | <b>Z</b> No Device   | <b>7</b> Atrium, Left  |
| FY2021    | <b>7</b> Atrium, Left   | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>8</b> Zooplasic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute<br><b>Z</b> No Device | <b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left<br><b>S</b> Pulmonary Vein, Right<br><b>T</b> Pulmonary Vein, Left<br><b>U</b> Pulmonary Vein, Confluence  |
| FY2021    | <b>7</b> Atrium, Left   | <b>3</b> Percutaneous                             | <b>J</b> Synthetic Substitute  | <b>6</b> Atrium, Right   |
| No change | <b>K</b> Ventricle, Right<br><b>L</b> Ventricle, Left   | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>8</b> Zooplasic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute                       | <b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left  |
| No change | <b>K</b> Ventricle, Right<br><b>L</b> Ventricle, Left   | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>Z</b> No Device   | <b>5</b> Coronary Circulation<br><b>8</b> Internal Mammary, Right<br><b>9</b> Internal Mammary, Left<br><b>C</b> Thoracic Artery<br><b>F</b> Abdominal Artery<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left<br><b>W</b> Aorta               |
| No change | <b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>8</b> Zooplasic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute<br><b>Z</b> No Device | <b>A</b> Innominate Artery<br><b>B</b> Subclavian<br><b>D</b> Carotid  |
| FY2021    | <b>V</b> Superior Vena Cava   | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic | <b>8</b> Zooplasic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute<br><b>Z</b> No Device | <b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left<br><b>S</b> Pulmonary Vein, Right<br><b>T</b> Pulmonary Vein, Left<br><b>U</b> Pulmonary Vein, Confluence  |
| No change | <b>W</b> Thoracic Aorta, Descending   | <b>0</b> Open                                     | <b>8</b> Zooplasic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute                       | <b>A</b> Innominate Artery<br><b>B</b> Subclavian<br><b>D</b> Carotid<br><b>F</b> Abdominal Artery<br><b>G</b> Axillary Artery<br><b>H</b> Brachial Artery<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left<br><b>V</b> Lower Extremity Artery |
| No change | <b>W</b> Thoracic Aorta, Descending   | <b>0</b> Open                                     | <b>Z</b> No Device   | <b>A</b> Innominate Artery<br><b>B</b> Subclavian<br><b>D</b> Carotid<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left   |
| No change | <b>W</b> Thoracic Aorta, Descending   | <b>4</b> Percutaneous Endoscopic                  | <b>8</b> Zooplasic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute<br><b>Z</b> No Device | <b>A</b> Innominate Artery<br><b>B</b> Subclavian<br><b>D</b> Carotid<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left   |

No change

|  |  |  |  |
|--|--|--|--|
| <b>X</b> Thoracic Aorta,<br>Ascending/Arch | <b>0</b> Open<br><b>4</b> Percutaneous<br>Endoscopic | <b>8</b> Zooplastic Tissue<br><b>9</b> Autologous Venous Tissue<br><b>A</b> Autologous Arterial Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue<br>Substitute<br><b>Z</b> No Device | <b>A</b> Innominate Artery<br><b>B</b> Subclavian<br><b>D</b> Carotid<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left |
|--|--|--|--|

## 02F

|           |  |   |                    |  |
|-----------|--|---|--------------------|--|
| No change | <i>Section</i> <b>0</b> Medical and Surgical   |   |                    |  |
|           | <i>Body System</i> <b>2</b> Heart and Great Vessels  |   |                    |  |
|           | <i>Operation</i> <b>F</b> Fragmentation: Breaking solid matter in a body part into pieces  |   |                    |  |
| Heading   | <i>Body Part</i>   | <i>Approach</i>   | <i>Device</i>      | <i>Qualifier</i>                             |
| No change | <b>N</b> Pericardium   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>X</b> External | <b>Z</b> No Device | <b>Z</b> No Qualifier                        |
| FY2021    | <b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left<br><b>S</b> Pulmonary Vein, Right<br><b>T</b> Pulmonary Vein, Left | <b>3</b> Percutaneous   | <b>Z</b> No Device | <b>0</b> Ultrasonic<br><b>Z</b> No Qualifier |

## 02U

|           |  |  |   |  |
|-----------|--|--|---|--|
| No change | <b>Section</b>   | <b>0</b>   | Medical and Surgical  |  |
|           | <b>Body System</b>   | <b>2</b>   | Heart and Great Vessels   |  |
|           | <b>Operation</b>   | <b>U</b>   | Supplement: Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part |  |
| Heading   | <b>Body Part</b>   | <b>Approach</b>  | <b>Device</b>   | <b>Qualifier</b>   |
| No change | <b>0</b> Coronary Artery, One Artery<br><b>1</b> Coronary Artery, Two Arteries<br><b>2</b> Coronary Artery, Three Arteries<br><b>3</b> Coronary Artery, Four or More Arteries<br><b>5</b> Atrial Septum<br><b>6</b> Atrium, Right<br><b>7</b> Atrium, Left<br><b>9</b> Chordae Tendineae<br><b>A</b> Heart<br><b>D</b> Papillary Muscle<br><b>H</b> Pulmonary Valve<br><b>K</b> Ventricle, Right<br><b>L</b> Ventricle, Left<br><b>M</b> Ventricular Septum<br><b>N</b> Pericardium<br><b>P</b> Pulmonary Trunk<br><b>Q</b> Pulmonary Artery, Right<br><b>R</b> Pulmonary Artery, Left<br><b>S</b> Pulmonary Vein, Right<br><b>T</b> Pulmonary Vein, Left<br><b>V</b> Superior Vena Cava<br><b>W</b> Thoracic Aorta, Descending<br><b>X</b> Thoracic Aorta, Ascending/Arch | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>7</b> Autologous Tissue Substitute<br><b>8</b> Zooplasic Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute   | <b>Z</b> No Qualifier  |
| No change | <b>F</b> Aortic Valve  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>7</b> Autologous Tissue Substitute<br><b>8</b> Zooplasic Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute   | <b>J</b> Truncal Valve<br><b>Z</b> No Qualifier  |
| FY2021    | <b>G</b> Mitral Valve  | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic                          | <b>7</b> Autologous Tissue Substitute<br><b>8</b> Zooplasic Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute   | <b>E</b> Atrioventricular Valve, Left<br><b>Z</b> No Qualifier                         |
| FY2021    | <b>G</b> Mitral Valve  | <b>3</b> Percutaneous  | <b>7</b> Autologous Tissue Substitute<br><b>8</b> Zooplasic Tissue<br><b>K</b> Nonautologous Tissue Substitute                                    | <b>E</b> Atrioventricular Valve, Left<br><b>Z</b> No Qualifier                         |
| FY2021    | <b>G</b> Mitral Valve  | <b>3</b> Percutaneous  | <b>J</b> Synthetic Substitute   | <b>E</b> Atrioventricular Valve, Left<br><b>H</b> Transapical<br><b>Z</b> No Qualifier |
| No change | <b>J</b> Tricuspid Valve   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>7</b> Autologous Tissue Substitute<br><b>8</b> Zooplasic Tissue<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute   | <b>G</b> Atrioventricular Valve, Right<br><b>Z</b> No Qualifier                        |



## 03F

|         |  |                       |                    |  |
|---------|--|-----------------------|--------------------|--|
| FY2021  | <i>Section</i> <b>0</b> Medical and Surgical   |                       |                    |  |
|         | <i>Body System</i> <b>3</b> Upper Arteries   |                       |                    |  |
|         | <i>Operation</i> <b>F</b> Fragmentation: Breaking solid matter in a body part into pieces  |                       |                    |  |
| Heading | <i>Body Part</i>   | <i>Approach</i>       | <i>Device</i>      | <i>Qualifier</i>                             |
| FY2021  | <b>2</b> Innominate Artery<br><b>3</b> Subclavian Artery, Right<br><b>4</b> Subclavian Artery, Left<br><b>5</b> Axillary Artery, Right<br><b>6</b> Axillary Artery, Left<br><b>7</b> Brachial Artery, Right<br><b>8</b> Brachial Artery, Left<br><b>9</b> Ulnar Artery, Right<br><b>A</b> Ulnar Artery, Left<br><b>B</b> Radial Artery, Right<br><b>C</b> Radial Artery, Left<br><b>Y</b> Upper Artery | <b>3</b> Percutaneous | <b>Z</b> No Device | <b>0</b> Ultrasonic<br><b>Z</b> No Qualifier |

## 04F

|         |   |                       |                    |  |
|---------|---|-----------------------|--------------------|--|
| FY2021  | <i>Section</i> <b>0</b> Medical and Surgical  |                       |                    |  |
|         | <i>Body System</i> <b>4</b> Lower Arteries  |                       |                    |  |
|         | <i>Operation</i> <b>F</b> Fragmentation: Breaking solid matter in a body part into pieces   |                       |                    |  |
| Heading | <i>Body Part</i>  | <i>Approach</i>       | <i>Device</i>      | <i>Qualifier</i>                             |
| FY2021  | <b>C</b> Common Iliac Artery, Right<br><b>D</b> Common Iliac Artery, Left<br><b>E</b> Internal Iliac Artery, Right<br><b>F</b> Internal Iliac Artery, Left<br><b>H</b> External Iliac Artery, Right<br><b>J</b> External Iliac Artery, Left<br><b>K</b> Femoral Artery, Right<br><b>L</b> Femoral Artery, Left<br><b>M</b> Popliteal Artery, Right<br><b>N</b> Popliteal Artery, Left<br><b>P</b> Anterior Tibial Artery, Right<br><b>Q</b> Anterior Tibial Artery, Left<br><b>R</b> Posterior Tibial Artery, Right<br><b>S</b> Posterior Tibial Artery, Left<br><b>T</b> Peroneal Artery, Right<br><b>U</b> Peroneal Artery, Left<br><b>Y</b> Lower Artery | <b>3</b> Percutaneous | <b>Z</b> No Device | <b>0</b> Ultrasonic<br><b>Z</b> No Qualifier |

## 05F

|         |   |                       |                    |  |
|---------|---|-----------------------|--------------------|--|
| FY2021  | <i>Section</i> <b>0</b> Medical and Surgical  |                       |                    |  |
|         | <i>Body System</i> <b>5</b> Upper Veins   |                       |                    |  |
|         | <i>Operation</i> <b>F</b> Fragmentation: Breaking solid matter in a body part into pieces   |                       |                    |  |
| Heading | <i>Body Part</i>  | <i>Approach</i>       | <i>Device</i>      | <i>Qualifier</i>                             |
| FY2021  | <b>3</b> Innominate Vein, Right<br><b>4</b> Innominate Vein, Left<br><b>5</b> Subclavian Vein, Right<br><b>6</b> Subclavian Vein, Left<br><b>7</b> Axillary Vein, Right<br><b>8</b> Axillary Vein, Left<br><b>9</b> Brachial Vein, Right<br><b>A</b> Brachial Vein, Left<br><b>B</b> Basilic Vein, Right<br><b>C</b> Basilic Vein, Left<br><b>D</b> Cephalic Vein, Right<br><b>F</b> Cephalic Vein, Left<br><b>Y</b> Upper Vein | <b>3</b> Percutaneous | <b>Z</b> No Device | <b>0</b> Ultrasonic<br><b>Z</b> No Qualifier |

## 06F

|         |  |                       |                    |  |
|---------|--|-----------------------|--------------------|--|
| FY2021  | <i>Section</i> <b>0</b> Medical and Surgical   |                       |                    |  |
|         | <i>Body System</i> <b>6</b> Lower Veins  |                       |                    |  |
|         | <i>Operation</i> <b>F</b> Fragmentation: Breaking solid matter in a body part into pieces  |                       |                    |  |
| Heading | <i>Body Part</i>   | <i>Approach</i>       | <i>Device</i>      | <i>Qualifier</i>                             |
| FY2021  | <b>C</b> Common Iliac Vein, Right<br><b>D</b> Common Iliac Vein, Left<br><b>F</b> External Iliac Vein, Right<br><b>G</b> External Iliac Vein, Left<br><b>H</b> Hypogastric Vein, Right<br><b>J</b> Hypogastric Vein, Left<br><b>M</b> Femoral Vein, Right<br><b>N</b> Femoral Vein, Left<br><b>P</b> Saphenous Vein, Right<br><b>Q</b> Saphenous Vein, Left<br><b>Y</b> Lower Vein | <b>3</b> Percutaneous | <b>Z</b> No Device | <b>0</b> Ultrasonic<br><b>Z</b> No Qualifier |

## 07H

|           |  |  |   |                       |
|-----------|--|--|---|-----------------------|
| No change | <i>Section</i> <b>0</b> Medical and Surgical   |  |   |                       |
|           | <i>Body System</i> <b>7</b> Lymphatic and Hemic Systems  |  |   |                       |
|           | <i>Operation</i> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |  |   |                       |
| Heading   | <i>Body Part</i>   | <i>Approach</i>  | <i>Device</i>   | <i>Qualifier</i>      |
| FY2021    | <b>K</b> Thoracic Duct<br><b>L</b> Cisterna Chyli<br><b>M</b> Thymus<br><b>N</b> Lymphatic<br><b>P</b> Spleen<br><b>T</b> Bone Marrow  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>1</b> Radioactive Element<br><b>3</b> Infusion Device<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |

## 09H

|                   |  |   |   |                       |
|-------------------|--|---|---|-----------------------|
| No change         | <b>Section</b> <b>0</b> Medical and Surgical   |   |   |                       |
|                   | <b>Body System</b> <b>9</b> Ear, Nose, Sinus   |   |   |                       |
| Heading<br>FY2021 | <b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |   |   |                       |
|                   | <b>Body Part</b>   | <b>Approach</b>   | <b>Device</b>   | <b>Qualifier</b>      |
|                   | <b>D</b> Inner Ear, Right<br><b>E</b> Inner Ear, Left  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>1</b> Radioactive Element<br><b>4</b> Hearing Device, Bone Conduction<br><b>5</b> Hearing Device, Single Channel Cochlear Prosthesis<br><b>6</b> Hearing Device, Multiple Channel Cochlear Prosthesis<br><b>S</b> Hearing Device | <b>Z</b> No Qualifier |
|                   | <b>H</b> Ear, Right<br><b>J</b> Ear, Left<br><b>K</b> Nasal Mucosa and Soft Tissue<br><b>Y</b> Sinus   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>Y</b> Other Device   | <b>Z</b> No Qualifier |
| FY2021            | <b>N</b> Nasopharynx   | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>B</b> Intraluminal Device, Airway  | <b>Z</b> No Qualifier |

# 0CH

|           |  |   |  |                       |
|-----------|--|---|--|-----------------------|
| No change | <i>Section</i>                             | <b>0</b>  | Medical and Surgical   |                       |
|           | <i>Body System</i>                         | <b>C</b>  | Mouth and Throat   |                       |
|           | <i>Operation</i>                           | <b>H</b>  | Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |                       |
| Heading   | <i>Body Part</i>                           | <i>Approach</i>   | <i>Device</i>  | <i>Qualifier</i>      |
| No change | <b>7</b> Tongue                            | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>X</b> External   | <b>1</b> Radioactive Element   | <b>Z</b> No Qualifier |
| FY2021    | <b>A</b> Salivary Gland<br><b>S</b> Larynx | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |
| FY2021    | <b>Y</b> Mouth and Throat                  | <b>0</b> Open<br><b>3</b> Percutaneous  | <b>1</b> Radioactive Element<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |
| FY2021    | <b>Y</b> Mouth and Throat                  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>B</b> Intraluminal Device, Airway<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |

# ODH

|           |   |   |  |                       |
|-----------|---|---|--|-----------------------|
| No change | <b>Section</b> <b>0</b> Medical and Surgical<br><b>Body System</b> <b>D</b> Gastrointestinal System<br><b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |   |  |                       |
| Heading   | <b>Body Part</b>  | <b>Approach</b>   | <b>Device</b>  | <b>Qualifier</b>      |
| No change | <b>0</b> Upper Intestinal Tract<br><b>D</b> Lower Intestinal Tract  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>Y</b> Other Device  | <b>Z</b> No Qualifier |
| No change | <b>5</b> Esophagus  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>D</b> Intraluminal Device<br><b>U</b> Feeding Device<br><b>Y</b> Other Device   | <b>Z</b> No Qualifier |
| No change | <b>5</b> Esophagus  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>B</b> Intraluminal Device, Airway<br><b>D</b> Intraluminal Device<br><b>U</b> Feeding Device<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| FY2021    | <b>6</b> Stomach  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>D</b> Intraluminal Device<br><b>M</b> Stimulator Lead<br><b>U</b> Feeding Device<br><b>Y</b> Other Device             | <b>Z</b> No Qualifier |
| FY2021    | <b>6</b> Stomach  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>D</b> Intraluminal Device<br><b>U</b> Feeding Device<br><b>Y</b> Other Device   | <b>Z</b> No Qualifier |
| FY2021    | <b>8</b> Small Intestine<br><b>9</b> Duodenum<br><b>A</b> Jejunum<br><b>B</b> Ileum   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>D</b> Intraluminal Device<br><b>U</b> Feeding Device  | <b>Z</b> No Qualifier |
| FY2021    | <b>E</b> Large Intestine<br><b>P</b> Rectum   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>D</b> Intraluminal Device   | <b>Z</b> No Qualifier |



|           |                         |  |   |                       |
|-----------|-------------------------|--|---|-----------------------|
| No change | <b>Q</b> Anus           | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic                                | <b>D</b> Intraluminal Device<br><b>L</b> Artificial Sphincter | <b>Z</b> No Qualifier |
| No change | <b>Q</b> Anus           | <b>7</b> Via Natural or<br>Artificial Opening<br><b>8</b> Via Natural or<br>Artificial Opening<br>Endoscopic | <b>D</b> Intraluminal Device                                  | <b>Z</b> No Qualifier |
| No change | <b>R</b> Anal Sphincter | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic                                | <b>M</b> Stimulator Lead                                      | <b>Z</b> No Qualifier |

# 0F1

|           |   |  |  |   |
|-----------|---|--|--|---|
| No change | <b>Section</b> <b>0</b> Medical and Surgical  |  |  |   |
|           | <b>Body System</b> <b>F</b> Hepatobiliary System and Pancreas   |  |  |   |
|           | <b>Operation</b> <b>1</b> Bypass: Altering the route of passage of the contents of a tubular body part  |  |  |   |
| Heading   | <b>Body Part</b>  | <b>Approach</b>                                      | <b>Device</b>                                      | <b>Qualifier</b>  |
| No change | <b>4</b> Gallbladder<br><b>5</b> Hepatic Duct, Right<br><b>6</b> Hepatic Duct, Left<br><b>7</b> Hepatic Duct, Common<br><b>8</b> Cystic Duct<br><b>9</b> Common Bile Duct | <b>0</b> Open<br><b>4</b> Percutaneous<br>Endoscopic | <b>D</b> Intraluminal Device<br><b>Z</b> No Device | <b>3</b> Duodenum<br><b>4</b> Stomach<br><b>5</b> Hepatic Duct, Right<br><b>6</b> Hepatic Duct, Left<br><b>7</b> Hepatic Duct, Caudate<br><b>8</b> Cystic Duct<br><b>9</b> Common Bile Duct<br><b>B</b> Small Intestine |
| FY2021    | <b>D</b> Pancreatic Duct  | <b>0</b> Open<br><b>4</b> Percutaneous<br>Endoscopic | <b>D</b> Intraluminal Device<br><b>Z</b> No Device | <b>3</b> Duodenum<br><b>4</b> Stomach<br><b>B</b> Small Intestine<br><b>C</b> Large Intestine   |
| FY2021    | <b>F</b> Pancreatic Duct,<br>Accessory<br><b>G</b> Pancreas   | <b>0</b> Open<br><b>4</b> Percutaneous<br>Endoscopic | <b>D</b> Intraluminal Device<br><b>Z</b> No Device | <b>3</b> Duodenum<br><b>B</b> Small Intestine<br><b>C</b> Large Intestine   |

# 0FH

|           |  |   |   |                       |
|-----------|--|---|---|-----------------------|
| No change | <b>Section</b> <b>0</b> Medical and Surgical   |   |   |                       |
|           | <b>Body System</b> <b>F</b> Hepatobiliary System and Pancreas  |   |   |                       |
|           | <b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |   |   |                       |
| Heading   | <b>Body Part</b>   | <b>Approach</b>   | <b>Device</b>   | <b>Qualifier</b>      |
| FY2021    | <b>0</b> Liver<br><b>4</b> Gallbladder<br><b>G</b> Pancreas  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>Y</b> Other Device                                 | <b>Z</b> No Qualifier |
| No change | <b>1</b> Liver, Right Lobe<br><b>2</b> Liver, Left Lobe  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>2</b> Monitoring Device<br><b>3</b> Infusion Device  | <b>Z</b> No Qualifier |
| No change | <b>B</b> Hepatobiliary Duct<br><b>D</b> Pancreatic Duct  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>D</b> Intraluminal Device<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |

## 0GH

|           |                          |   |  |   |
|-----------|--------------------------|---|--|---|
| No change | <i>Section</i>           | <b>0</b>  | Medical and Surgical   |   |
|           | <i>Body System</i>       | <b>G</b>  | Endocrine System   |   |
|           | <i>Operation</i>         | <b>H</b>  | Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |   |
| Heading   | <i>Body Part</i>         | <i>Approach</i>   |  | <i>Device</i>   |
| FY2021    | <b>S</b> Endocrine Gland | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic |  | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>Y</b> Other Device |
|           |                          |   |  | <b>Z</b> No Qualifier   |

# 0JH

|           |   |  |                          |                       |
|-----------|---|--|--------------------------|-----------------------|
| No change | <i>Section</i> <b>0</b> Medical and Surgical  |  |                          |                       |
|           | <i>Body System</i> <b>J</b> Subcutaneous Tissue and Fascia  |  |                          |                       |
|           | <i>Operation</i> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part  |  |                          |                       |
| Heading   | <i>Body Part</i>  | <i>Approach</i>                        | <i>Device</i>            | <i>Qualifier</i>      |
| No change | <b>0</b> Subcutaneous Tissue and Fascia, Scalp<br><b>1</b> Subcutaneous Tissue and Fascia, Face<br><b>4</b> Subcutaneous Tissue and Fascia, Right Neck<br><b>5</b> Subcutaneous Tissue and Fascia, Left Neck<br><b>9</b> Subcutaneous Tissue and Fascia, Buttock<br><b>B</b> Subcutaneous Tissue and Fascia, Perineum<br><b>C</b> Subcutaneous Tissue and Fascia, Pelvic Region<br><b>J</b> Subcutaneous Tissue and Fascia, Right Hand<br><b>K</b> Subcutaneous Tissue and Fascia, Left Hand<br><b>Q</b> Subcutaneous Tissue and Fascia, Right Foot<br><b>R</b> Subcutaneous Tissue and Fascia, Left Foot | <b>0</b> Open<br><b>3</b> Percutaneous | <b>N</b> Tissue Expander | <b>Z</b> No Qualifier |

FY2021

|  |  |   |                       |
|--|--|---|-----------------------|
| <b>6</b> Subcutaneous Tissue and Fascia, Chest | <b>0</b> Open<br><b>3</b> Percutaneous | <b>0</b> Monitoring Device, Hemodynamic<br><b>2</b> Monitoring Device<br><b>4</b> Pacemaker, Single Chamber<br><b>5</b> Pacemaker, Single Chamber Rate Responsive<br><b>6</b> Pacemaker, Dual Chamber<br><b>7</b> Cardiac Resynchronization Pacemaker Pulse Generator<br><b>8</b> Defibrillator Generator<br><b>9</b> Cardiac Resynchronization Defibrillator Pulse Generator<br><b>A</b> Contractility Modulation Device<br><b>B</b> Stimulator Generator, Single Array<br><b>C</b> Stimulator Generator, Single Array Rechargeable<br><b>D</b> Stimulator Generator, Multiple Array<br><b>E</b> Stimulator Generator, Multiple Array Rechargeable<br><b>F</b> Subcutaneous Defibrillator Lead<br><b>H</b> Contraceptive Device<br><b>M</b> Stimulator Generator<br><b>N</b> Tissue Expander<br><b>P</b> Cardiac Rhythm Related Device<br><b>V</b> Infusion Device, Pump<br><b>W</b> Vascular Access Device, Totally Implantable<br><b>X</b> Vascular Access Device, Tunneled<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| <b>7</b> Subcutaneous Tissue and Fascia, Back  | <b>0</b> Open<br><b>3</b> Percutaneous | <b>B</b> Stimulator Generator, Single Array<br><b>C</b> Stimulator Generator, Single Array Rechargeable<br><b>D</b> Stimulator Generator, Multiple Array<br><b>E</b> Stimulator Generator, Multiple Array Rechargeable<br><b>M</b> Stimulator Generator<br><b>N</b> Tissue Expander<br><b>V</b> Infusion Device, Pump<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |

FY2021

|           |  |  |   |                       |
|-----------|--|--|---|-----------------------|
|           | <b>8</b> Subcutaneous Tissue and Fascia, Abdomen   | <b>0</b> Open<br><b>3</b> Percutaneous | <b>0</b> Monitoring Device, Hemodynamic<br><b>2</b> Monitoring Device<br><b>4</b> Pacemaker, Single Chamber<br><b>5</b> Pacemaker, Single Chamber Rate Responsive<br><b>6</b> Pacemaker, Dual Chamber<br><b>7</b> Cardiac Resynchronization Pacemaker Pulse Generator<br><b>8</b> Defibrillator Generator<br><b>9</b> Cardiac Resynchronization Defibrillator Pulse Generator<br><b>A</b> Contractility Modulation Device<br><b>B</b> Stimulator Generator, Single Array<br><b>C</b> Stimulator Generator, Single Array Rechargeable<br><b>D</b> Stimulator Generator, Multiple Array<br><b>E</b> Stimulator Generator, Multiple Array Rechargeable<br><b>H</b> Contraceptive Device<br><b>M</b> Stimulator Generator<br><b>N</b> Tissue Expander<br><b>P</b> Cardiac Rhythm Related Device<br><b>V</b> Infusion Device, Pump<br><b>W</b> Vascular Access Device, Totally Implantable<br><b>X</b> Vascular Access Device, Tunneled<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| No change | <b>D</b> Subcutaneous Tissue and Fascia, Right Upper Arm<br><b>F</b> Subcutaneous Tissue and Fascia, Left Upper Arm<br><b>G</b> Subcutaneous Tissue and Fascia, Right Lower Arm<br><b>H</b> Subcutaneous Tissue and Fascia, Left Lower Arm<br><b>L</b> Subcutaneous Tissue and Fascia, Right Upper Leg<br><b>M</b> Subcutaneous Tissue and Fascia, Left Upper Leg<br><b>N</b> Subcutaneous Tissue and Fascia, Right Lower Leg<br><b>P</b> Subcutaneous Tissue and Fascia, Left Lower Leg | <b>0</b> Open<br><b>3</b> Percutaneous | <b>H</b> Contraceptive Device<br><b>N</b> Tissue Expander<br><b>V</b> Infusion Device, Pump<br><b>W</b> Vascular Access Device, Totally Implantable<br><b>X</b> Vascular Access Device, Tunneled  | <b>Z</b> No Qualifier |
| No change | <b>S</b> Subcutaneous Tissue and Fascia, Head and Neck<br><b>V</b> Subcutaneous Tissue and Fascia, Upper Extremity<br><b>W</b> Subcutaneous Tissue and Fascia, Lower Extremity   | <b>0</b> Open<br><b>3</b> Percutaneous | <b>1</b> Radioactive Element<br><b>3</b> Infusion Device<br><b>Y</b> Other Device   | <b>Z</b> No Qualifier |
| No change | <b>T</b> Subcutaneous Tissue and Fascia, Trunk   | <b>0</b> Open<br><b>3</b> Percutaneous | <b>1</b> Radioactive Element<br><b>3</b> Infusion Device<br><b>V</b> Infusion Device, Pump<br><b>Y</b> Other Device   | <b>Z</b> No Qualifier |

# 0QP

|           |   |   |  |                       |
|-----------|---|---|--|-----------------------|
| No change | <b>Section</b> <b>0</b> Medical and Surgical  |   |  |                       |
|           | <b>Body System</b> <b>Q</b> Lower Bones   |   |  |                       |
|           | <b>Operation</b> <b>P</b> Removal: Taking out or off a device from a body part  |   |  |                       |
| Heading   | <b>Body Part</b>  | <b>Approach</b>   | <b>Device</b>  | <b>Qualifier</b>      |
| FY2021    | <b>0</b> Lumbar Vertebra<br><b>1</b> Sacrum<br><b>2</b> Pelvic Bone, Right<br><b>3</b> Pelvic Bone, Left<br><b>4</b> Acetabulum, Right<br><b>5</b> Acetabulum, Left<br><b>6</b> Upper Femur, Right<br><b>7</b> Upper Femur, Left<br><b>8</b> Femoral Shaft, Right<br><b>9</b> Femoral Shaft, Left<br><b>B</b> Lower Femur, Right<br><b>C</b> Lower Femur, Left<br><b>D</b> Patella, Right<br><b>F</b> Patella, Left<br><b>G</b> Tibia, Right<br><b>H</b> Tibia, Left<br><b>J</b> Fibula, Right<br><b>K</b> Fibula, Left<br><b>L</b> Tarsal, Right<br><b>M</b> Tarsal, Left<br><b>N</b> Metatarsal, Right<br><b>P</b> Metatarsal, Left<br><b>Q</b> Toe Phalanx, Right<br><b>R</b> Toe Phalanx, Left<br><b>S</b> Coccyx | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic                      | <b>4</b> Internal Fixation Device<br><b>5</b> External Fixation Device<br><b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute | <b>Z</b> No Qualifier |
| FY2021    | <b>0</b> Lumbar Vertebra<br><b>1</b> Sacrum<br><b>2</b> Pelvic Bone, Right<br><b>3</b> Pelvic Bone, Left<br><b>4</b> Acetabulum, Right<br><b>5</b> Acetabulum, Left<br><b>6</b> Upper Femur, Right<br><b>7</b> Upper Femur, Left<br><b>8</b> Femoral Shaft, Right<br><b>9</b> Femoral Shaft, Left<br><b>B</b> Lower Femur, Right<br><b>C</b> Lower Femur, Left<br><b>D</b> Patella, Right<br><b>F</b> Patella, Left<br><b>G</b> Tibia, Right<br><b>H</b> Tibia, Left<br><b>J</b> Fibula, Right<br><b>K</b> Fibula, Left<br><b>L</b> Tarsal, Right<br><b>M</b> Tarsal, Left<br><b>N</b> Metatarsal, Right<br><b>P</b> Metatarsal, Left<br><b>Q</b> Toe Phalanx, Right<br><b>R</b> Toe Phalanx, Left<br><b>S</b> Coccyx | <b>X</b> External   | <b>4</b> Internal Fixation Device<br><b>5</b> External Fixation Device   | <b>Z</b> No Qualifier |
| No change | <b>Y</b> Lower Bone   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>X</b> External | <b>0</b> Drainage Device<br><b>M</b> Bone Growth Stimulator  | <b>Z</b> No Qualifier |



# ORG

|           |  |  |  |  |
|-----------|--|--|--|--|
| No change | <b>Section</b> <b>0</b> Medical and Surgical<br><b>Body System</b> <b>R</b> Upper Joints<br><b>Operation</b> <b>G</b> Fusion: Joining together portions of an articular body part rendering the articular body part immobile   |  |  |  |
|           |  |  |  |  |
| Heading   | <b>Body Part</b>   | <b>Approach</b>  | <b>Device</b>  | <b>Qualifier</b>   |
| No change | <b>0</b> Occipital-cervical Joint<br><b>1</b> Cervical Vertebral Joint<br><b>2</b> Cervical Vertebral Joints, 2 or more<br><b>4</b> Cervicothoracic Vertebral Joint<br><b>6</b> Thoracic Vertebral Joint<br><b>7</b> Thoracic Vertebral Joints, 2 to 7<br><b>8</b> Thoracic Vertebral Joints, 8 or more<br><b>A</b> Thoracolumbar Vertebral Joint  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute   | <b>0</b> Anterior Approach, Anterior Column<br><b>1</b> Posterior Approach, Posterior Column<br><b>J</b> Posterior Approach, Anterior Column |
| No change | <b>0</b> Occipital-cervical Joint<br><b>1</b> Cervical Vertebral Joint<br><b>2</b> Cervical Vertebral Joints, 2 or more<br><b>4</b> Cervicothoracic Vertebral Joint<br><b>6</b> Thoracic Vertebral Joint<br><b>7</b> Thoracic Vertebral Joints, 2 to 7<br><b>8</b> Thoracic Vertebral Joints, 8 or more<br><b>A</b> Thoracolumbar Vertebral Joint  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>A</b> Interbody Fusion Device   | <b>0</b> Anterior Approach, Anterior Column<br><b>J</b> Posterior Approach, Anterior Column  |
| No change | <b>C</b> Temporomandibular Joint, Right<br><b>D</b> Temporomandibular Joint, Left<br><b>E</b> Sternoclavicular Joint, Right<br><b>F</b> Sternoclavicular Joint, Left<br><b>G</b> Acromioclavicular Joint, Right<br><b>H</b> Acromioclavicular Joint, Left<br><b>J</b> Shoulder Joint, Right<br><b>K</b> Shoulder Joint, Left   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>4</b> Internal Fixation Device<br><b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute  | <b>Z</b> No Qualifier  |
| FY2021    | <b>L</b> Elbow Joint, Right<br><b>M</b> Elbow Joint, Left<br><b>N</b> Wrist Joint, Right<br><b>P</b> Wrist Joint, Left<br><b>Q</b> Carpal Joint, Right<br><b>R</b> Carpal Joint, Left<br><b>S</b> Carpometacarpal Joint, Right<br><b>T</b> Carpometacarpal Joint, Left<br><b>U</b> Metacarpophalangeal Joint, Right<br><b>V</b> Metacarpophalangeal Joint, Left<br><b>W</b> Finger Phalangeal Joint, Right<br><b>X</b> Finger Phalangeal Joint, Left | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>3</b> Internal Fixation Device, Sustained Compression<br><b>4</b> Internal Fixation Device<br><b>5</b> External Fixation Device<br><b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute | <b>Z</b> No Qualifier  |

# OSG

|           |   |  |  |  |
|-----------|---|--|--|--|
| No change | <b>Section</b> <b>0</b> Medical and Surgical  |  |  |  |
|           | <b>Body System</b> <b>S</b> Lower Joints  |  |  |  |
|           | <b>Operation</b> <b>G</b> Fusion: Joining together portions of an articular body part rendering the articular body part immobile  |  |  |  |
| Heading   | <b>Body Part</b>  | <b>Approach</b>  | <b>Device</b>  | <b>Qualifier</b>   |
| No change | <b>0</b> Lumbar Vertebral Joint<br><b>1</b> Lumbar Vertebral Joints, 2 or more<br><b>3</b> Lumbosacral Joint  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute   | <b>0</b> Anterior Approach, Anterior Column<br><b>1</b> Posterior Approach, Posterior Column<br><b>J</b> Posterior Approach, Anterior Column |
| No change | <b>0</b> Lumbar Vertebral Joint<br><b>1</b> Lumbar Vertebral Joints, 2 or more<br><b>3</b> Lumbosacral Joint  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>A</b> Interbody Fusion Device   | <b>0</b> Anterior Approach, Anterior Column<br><b>J</b> Posterior Approach, Anterior Column  |
| No change | <b>5</b> Sacrococcygeal Joint<br><b>6</b> Coccygeal Joint<br><b>7</b> Sacroiliac Joint, Right<br><b>8</b> Sacroiliac Joint, Left  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>4</b> Internal Fixation Device<br><b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute  | <b>Z</b> No Qualifier  |
| FY2021    | <b>9</b> Hip Joint, Right<br><b>B</b> Hip Joint, Left<br><b>C</b> Knee Joint, Right<br><b>D</b> Knee Joint, Left<br><b>F</b> Ankle Joint, Right<br><b>G</b> Ankle Joint, Left<br><b>H</b> Tarsal Joint, Right<br><b>J</b> Tarsal Joint, Left<br><b>K</b> Tarsometatarsal Joint, Right<br><b>L</b> Tarsometatarsal Joint, Left<br><b>M</b> Metatarsal-Phalangeal Joint, Right<br><b>N</b> Metatarsal-Phalangeal Joint, Left<br><b>P</b> Toe Phalangeal Joint, Right<br><b>Q</b> Toe Phalangeal Joint, Left | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>3</b> Internal Fixation Device, Sustained Compression<br><b>4</b> Internal Fixation Device<br><b>5</b> External Fixation Device<br><b>7</b> Autologous Tissue Substitute<br><b>J</b> Synthetic Substitute<br><b>K</b> Nonautologous Tissue Substitute | <b>Z</b> No Qualifier  |

# OTH

|           |                       |   |  |                       |
|-----------|-----------------------|---|--|-----------------------|
| No change | <i>Section</i>        | <b>0</b>  | Medical and Surgical   |                       |
|           | <i>Body System</i>    | <b>T</b>  | Urinary System   |                       |
|           | <i>Operation</i>      | <b>H</b>  | Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |                       |
| Heading   | <i>Body Part</i>      | <i>Approach</i>   | <i>Device</i>  | <i>Qualifier</i>      |
| FY2021    | <b>5</b> Kidney       | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>Y</b> Other Device  | <b>Z</b> No Qualifier |
| FY2021    | <b>9</b> Ureter       | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>M</b> Stimulator Lead<br><b>Y</b> Other Device                                  | <b>Z</b> No Qualifier |
| FY2021    | <b>B</b> Bladder      | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>L</b> Artificial Sphincter<br><b>M</b> Stimulator Lead<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| No change | <b>C</b> Bladder Neck | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>L</b> Artificial Sphincter  | <b>Z</b> No Qualifier |
| FY2021    | <b>D</b> Urethra      | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>L</b> Artificial Sphincter<br><b>Y</b> Other Device                             | <b>Z</b> No Qualifier |
| No change | <b>D</b> Urethra      | <b>X</b> External   | <b>2</b> Monitoring Device<br><b>3</b> Infusion Device<br><b>L</b> Artificial Sphincter  | <b>Z</b> No Qualifier |

# OUH

|           |  |   |   |                       |
|-----------|--|---|---|-----------------------|
| No change | <b>Section</b> <b>0</b> Medical and Surgical<br><b>Body System</b> <b>U</b> Female Reproductive System<br><b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |   |   |                       |
| Heading   | <b>Body Part</b>   | <b>Approach</b>   | <b>Device</b>   | <b>Qualifier</b>      |
| FY2021    | <b>3</b> Ovary   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>1</b> Radioactive Element<br><b>3</b> Infusion Device<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| FY2021    | <b>3</b> Ovary   | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>Y</b> Other Device                             | <b>Z</b> No Qualifier |
| No change | <b>8</b> Fallopian Tube<br><b>D</b> Uterus and Cervix<br><b>H</b> Vagina and Cul-de-sac  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>3</b> Infusion Device<br><b>Y</b> Other Device                                 | <b>Z</b> No Qualifier |
| FY2021    | <b>9</b> Uterus  | <b>0</b> Open<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic  | <b>1</b> Radioactive Element<br><b>H</b> Contraceptive Device                     | <b>Z</b> No Qualifier |
| No change | <b>C</b> Cervix  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>1</b> Radioactive Element  | <b>Z</b> No Qualifier |
| No change | <b>C</b> Cervix  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>H</b> Contraceptive Device                     | <b>Z</b> No Qualifier |
| No change | <b>F</b> Cul-de-sac  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>G</b> Intraluminal Device, Pessary   | <b>Z</b> No Qualifier |
| No change | <b>G</b> Vagina  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>X</b> External   | <b>1</b> Radioactive Element  | <b>Z</b> No Qualifier |
| No change | <b>G</b> Vagina  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>1</b> Radioactive Element<br><b>G</b> Intraluminal Device, Pessary             | <b>Z</b> No Qualifier |

# OVH

|           |  |   |   |                       |
|-----------|--|---|---|-----------------------|
| No change | <b>Section</b> <b>0</b> Medical and Surgical<br><b>Body System</b> <b>V</b> Male Reproductive System<br><b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part |   |   |                       |
| Heading   | <b>Body Part</b>   | <b>Approach</b>   | <b>Device</b>   | <b>Qualifier</b>      |
| No change | <b>0</b> Prostate  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element  | <b>Z</b> No Qualifier |
| FY2021    | <b>4</b> Prostate and Seminal Vesicles<br><b>8</b> Scrotum and Tunica Vaginalis<br><b>M</b> Epididymis and Spermatic Cord<br><b>R</b> Vas Deferens   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>3</b> Infusion Device<br><b>Y</b> Other Device                                 | <b>Z</b> No Qualifier |
| FY2021    | <b>D</b> Testis  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>1</b> Radioactive Element<br><b>3</b> Infusion Device<br><b>Y</b> Other Device | <b>Z</b> No Qualifier |
| No change | <b>S</b> Penis   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>3</b> Infusion Device<br><b>Y</b> Other Device                                 | <b>Z</b> No Qualifier |
| No change | <b>S</b> Penis   | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic   | <b>Y</b> Other Device   | <b>Z</b> No Qualifier |
| No change | <b>S</b> Penis   | <b>X</b> External   | <b>3</b> Infusion Device  | <b>Z</b> No Qualifier |

# 0VY

|         |                                    |                 |  |   |
|---------|------------------------------------|-----------------|--|---|
| FY2021  | <i>Section</i>                     | <b>0</b>        | Medical and Surgical   |   |
|         | <i>Body System</i>                 | <b>V</b>        | Male Reproductive System   |   |
|         | <i>Operation</i>                   | <b>Y</b>        | Transplantation: Putting in or on all or a portion of a living body part taken from another individual or animal to physically take the place and/or function of all or a portion of a similar body part |   |
| Heading | <i>Body Part</i>                   | <i>Approach</i> | <i>Device</i>  | <i>Qualifier</i>  |
| FY2021  | <b>5</b> Scrotum<br><b>S</b> Penis | <b>0</b> Open   | <b>Z</b> No Device   | <b>0</b> Allogeneic<br><b>1</b> Syngeneic<br><b>2</b> Zooplasic |

# 0W1

|           |  |   |                               |   |
|-----------|--|---|-------------------------------|---|
| No change | <i>Section</i> <b>0</b> Medical and Surgical   |   |                               |   |
|           | <i>Body System</i> <b>W</b> Anatomical Regions, General  |   |                               |   |
|           | <i>Operation</i> <b>1</b> Bypass: Altering the route of passage of the contents of a tubular body part |   |                               |   |
| Heading   | <i>Body Part</i>   | <i>Approach</i>   | <i>Device</i>                 | <i>Qualifier</i>  |
| No change | <b>1</b> Cranial Cavity  | <b>0</b> Open   | <b>J</b> Synthetic Substitute | <b>9</b> Pleural Cavity, Right<br><b>B</b> Pleural Cavity, Left<br><b>G</b> Peritoneal Cavity<br><b>J</b> Pelvic Cavity   |
| FY2021    | <b>9</b> Pleural Cavity, Right<br><b>B</b> Pleural Cavity, Left<br><b>J</b> Pelvic Cavity              | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic | <b>J</b> Synthetic Substitute | <b>4</b> Cutaneous<br><b>9</b> Pleural Cavity, Right<br><b>B</b> Pleural Cavity, Left<br><b>G</b> Peritoneal Cavity<br><b>J</b> Pelvic Cavity<br><b>W</b> Upper Vein<br><b>Y</b> Lower Vein                     |
| FY2021    | <b>G</b> Peritoneal Cavity   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic | <b>J</b> Synthetic Substitute | <b>4</b> Cutaneous<br><b>6</b> Bladder<br><b>9</b> Pleural Cavity, Right<br><b>B</b> Pleural Cavity, Left<br><b>G</b> Peritoneal Cavity<br><b>J</b> Pelvic Cavity<br><b>W</b> Upper Vein<br><b>Y</b> Lower Vein |

# 0W9

|           |   |   |                          |  |
|-----------|---|---|--------------------------|--|
| No change | <b>Section</b> <b>0</b> Medical and Surgical  |   |                          |  |
|           | <b>Body System</b> <b>W</b> Anatomical Regions, General   |   |                          |  |
|           | <b>Operation</b> <b>9</b> Drainage: Taking or letting out fluids and/or gases from a body part  |   |                          |  |
| Heading   | <b>Body Part</b>  | <b>Approach</b>   | <b>Device</b>            | <b>Qualifier</b>                             |
| FY2021    | <b>0</b> Head<br><b>1</b> Cranial Cavity<br><b>2</b> Face<br><b>3</b> Oral Cavity and Throat<br><b>4</b> Upper Jaw<br><b>5</b> Lower Jaw<br><b>6</b> Neck<br><b>8</b> Chest Wall<br><b>9</b> Pleural Cavity, Right<br><b>B</b> Pleural Cavity, Left<br><b>C</b> Mediastinum<br><b>D</b> Pericardial Cavity<br><b>F</b> Abdominal Wall<br><b>G</b> Peritoneal Cavity<br><b>H</b> Retroperitoneum<br><b>K</b> Upper Back<br><b>L</b> Lower Back<br><b>M</b> Perineum, Male<br><b>N</b> Perineum, Female | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>0</b> Drainage Device | <b>Z</b> No Qualifier                        |
| FY2021    | <b>0</b> Head<br><b>1</b> Cranial Cavity<br><b>2</b> Face<br><b>3</b> Oral Cavity and Throat<br><b>4</b> Upper Jaw<br><b>5</b> Lower Jaw<br><b>6</b> Neck<br><b>8</b> Chest Wall<br><b>9</b> Pleural Cavity, Right<br><b>B</b> Pleural Cavity, Left<br><b>C</b> Mediastinum<br><b>D</b> Pericardial Cavity<br><b>F</b> Abdominal Wall<br><b>G</b> Peritoneal Cavity<br><b>H</b> Retroperitoneum<br><b>K</b> Upper Back<br><b>L</b> Lower Back<br><b>M</b> Perineum, Male<br><b>N</b> Perineum, Female | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic  | <b>Z</b> No Device       | <b>X</b> Diagnostic<br><b>Z</b> No Qualifier |
| FY2021    | <b>J</b> Pelvic Cavity  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>0</b> Drainage Device | <b>Z</b> No Qualifier                        |
| FY2021    | <b>J</b> Pelvic Cavity  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>Z</b> No Device       | <b>X</b> Diagnostic<br><b>Z</b> No Qualifier |



# 10D

|           |  |  |                    |   |
|-----------|--|--|--------------------|---|
| No change | <b>Section</b> <b>1</b> Obstetrics<br><b>Body System</b> <b>0</b> Pregnancy<br><b>Operation</b> <b>D</b> Extraction: Pulling or stripping out or off all or a portion of a body part by the use of force |  |                    |   |
| Heading   | <b>Body Part</b>   | <b>Approach</b>  | <b>Device</b>      | <b>Qualifier</b>  |
| No change | <b>0</b> Products of Conception  | <b>0</b> Open  | <b>Z</b> No Device | <b>0</b> High<br><b>1</b> Low<br><b>2</b> Extraperitoneal   |
| No change | <b>0</b> Products of Conception  | <b>7</b> Via Natural or Artificial Opening   | <b>Z</b> No Device | <b>3</b> Low Forceps<br><b>4</b> Mid Forceps<br><b>5</b> High Forceps<br><b>6</b> Vacuum<br><b>7</b> Internal Version<br><b>8</b> Other |
| No change | <b>1</b> Products of Conception, Retained  | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic  | <b>Z</b> No Device | <b>9</b> Manual<br><b>Z</b> No Qualifier  |
| FY2021    | <b>2</b> Products of Conception, Ectopic   | <b>0</b> Open<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>Z</b> No Device | <b>Z</b> No Qualifier   |

302

|           |  |   |  |   |
|-----------|--|---|--|---|
| No change | <b>Section 3 Administration</b>                                    |   |  |   |
|           | <b>Body System 0 Circulatory</b>                                   |   |  |   |
|           | <b>Operation 2 Transfusion: Putting in blood or blood products</b> |   |  |   |
| Heading   | <b>Body System / Region</b>  | <b>Approach</b>   | <b>Substance</b>   | <b>Qualifier</b>  |
| No change | <b>3 Peripheral Vein</b><br><b>4 Central Vein</b>                  | <b>0 Open</b><br><b>3 Percutaneous</b>                              | <b>A Stem Cells, Embryonic</b>   | <b>Z No Qualifier</b>   |
| FY2021    | <b>3 Peripheral Vein</b><br><b>4 Central Vein</b>                  | <b>0 Open</b><br><b>3 Percutaneous</b>                              | <b>C Hematopoietic Stem/Progenitor Cells, Genetically Modified</b>   | <b>0 Autologous</b>   |
| No change | <b>3 Peripheral Vein</b><br><b>4 Central Vein</b>                  | <b>0 Open</b><br><b>3 Percutaneous</b>                              | <b>G Bone Marrow</b><br><b>X Stem Cells, Cord Blood</b><br><b>Y Stem Cells, Hematopoietic</b>  | <b>0 Autologous</b><br><b>2 Allogeneic, Related</b><br><b>3 Allogeneic, Unrelated</b><br><b>4 Allogeneic, Unspecified</b> |
| No change | <b>3 Peripheral Vein</b><br><b>4 Central Vein</b>                  | <b>0 Open</b><br><b>3 Percutaneous</b>                              | <b>H Whole Blood</b><br><b>J Serum Albumin</b><br><b>K Frozen Plasma</b><br><b>L Fresh Plasma</b><br><b>M Plasma Cryoprecipitate</b><br><b>N Red Blood Cells</b><br><b>P Frozen Red Cells</b><br><b>Q White Cells</b><br><b>R Platelets</b><br><b>S Globulin</b><br><b>T Fibrinogen</b><br><b>V Antihemophilic Factors</b><br><b>W Factor IX</b> | <b>0 Autologous</b><br><b>1 Nonautologous</b>   |
| No change | <b>3 Peripheral Vein</b><br><b>4 Central Vein</b>                  | <b>0 Open</b><br><b>3 Percutaneous</b>                              | <b>U Stem Cells, T-cell Depleted Hematopoietic</b>   | <b>2 Allogeneic, Related</b><br><b>3 Allogeneic, Unrelated</b><br><b>4 Allogeneic, Unspecified</b>                        |
| No change | <b>7 Products of Conception, Circulatory</b>                       | <b>3 Percutaneous</b><br><b>7 Via Natural or Artificial Opening</b> | <b>H Whole Blood</b><br><b>J Serum Albumin</b><br><b>K Frozen Plasma</b><br><b>L Fresh Plasma</b><br><b>M Plasma Cryoprecipitate</b><br><b>N Red Blood Cells</b><br><b>P Frozen Red Cells</b><br><b>Q White Cells</b><br><b>R Platelets</b><br><b>S Globulin</b><br><b>T Fibrinogen</b><br><b>V Antihemophilic Factors</b><br><b>W Factor IX</b> | <b>1 Nonautologous</b>  |
| No change | <b>8 Vein</b>  | <b>0 Open</b><br><b>3 Percutaneous</b>                              | <b>B 4-Factor Prothrombin Complex Concentrate</b>  | <b>1 Nonautologous</b>  |

## 4A0

|           |   |  |   |   |
|-----------|---|--|---|---|
| No change | <b>Section 4</b> Measurement and Monitoring<br><b>Body System A</b> Physiological Systems<br><b>Operation 0</b> Measurement: Determining the level of a physiological or physical function at a point in time |  |   |   |
| Heading   | <b>Body System</b>  | <b>Approach</b>  | <b>Function / Device</b>  | <b>Qualifier</b>  |
| No change | <b>0</b> Central Nervous  | <b>0</b> Open  | <b>2</b> Conductivity<br><b>4</b> Electrical Activity<br><b>B</b> Pressure  | <b>Z</b> No Qualifier   |
| No change | <b>0</b> Central Nervous  | <b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic                                       | <b>4</b> Electrical Activity  | <b>Z</b> No Qualifier   |
| No change | <b>0</b> Central Nervous  | <b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic                                       | <b>B</b> Pressure<br><b>K</b> Temperature<br><b>R</b> Saturation  | <b>D</b> Intracranial   |
| No change | <b>0</b> Central Nervous  | <b>X</b> External  | <b>2</b> Conductivity<br><b>4</b> Electrical Activity   | <b>Z</b> No Qualifier   |
| No change | <b>1</b> Peripheral Nervous   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic<br><b>X</b> External | <b>2</b> Conductivity   | <b>9</b> Sensory<br><b>B</b> Motor                                |
| No change | <b>1</b> Peripheral Nervous   | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic<br><b>X</b> External | <b>4</b> Electrical Activity  | <b>Z</b> No Qualifier   |
| No change | <b>2</b> Cardiac  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic                      | <b>4</b> Electrical Activity<br><b>9</b> Output<br><b>C</b> Rate<br><b>F</b> Rhythm<br><b>H</b> Sound<br><b>P</b> Action Currents | <b>Z</b> No Qualifier   |
| No change | <b>2</b> Cardiac  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic                      | <b>N</b> Sampling and Pressure  | <b>6</b> Right Heart<br><b>7</b> Left Heart<br><b>8</b> Bilateral |
| No change | <b>2</b> Cardiac  | <b>X</b> External  | <b>4</b> Electrical Activity  | <b>A</b> Guidance<br><b>Z</b> No Qualifier                        |
| No change | <b>2</b> Cardiac  | <b>X</b> External  | <b>9</b> Output<br><b>C</b> Rate<br><b>F</b> Rhythm<br><b>H</b> Sound<br><b>P</b> Action Currents                                 | <b>Z</b> No Qualifier   |
| No change | <b>2</b> Cardiac  | <b>X</b> External  | <b>M</b> Total Activity   | <b>4</b> Stress   |

|           |                           |  |  |   |
|-----------|---------------------------|--|--|---|
| No change | <b>3</b> Arterial         | <b>0</b> Open<br><b>3</b> Percutaneous   | <b>5</b> Flow<br><b>J</b> Pulse  | <b>1</b> Peripheral<br><b>3</b> Pulmonary<br><b>C</b> Coronary                            |
| No change | <b>3</b> Arterial         | <b>0</b> Open<br><b>3</b> Percutaneous   | <b>B</b> Pressure  | <b>1</b> Peripheral<br><b>3</b> Pulmonary<br><b>C</b> Coronary<br><b>F</b> Other Thoracic |
| No change | <b>3</b> Arterial         | <b>0</b> Open<br><b>3</b> Percutaneous   | <b>H</b> Sound<br><b>R</b> Saturation  | <b>1</b> Peripheral   |
| FY2021    | <b>3</b> Arterial         | <b>X</b> External  | <b>5</b> Flow  | <b>1</b> Peripheral<br><b>D</b> Intracranial  |
| FY2021    | <b>3</b> Arterial         | <b>X</b> External  | <b>B</b> Pressure<br><b>H</b> Sound<br><b>J</b> Pulse<br><b>R</b> Saturation   | <b>1</b> Peripheral   |
| No change | <b>4</b> Venous           | <b>0</b> Open<br><b>3</b> Percutaneous   | <b>5</b> Flow<br><b>B</b> Pressure<br><b>J</b> Pulse   | <b>0</b> Central<br><b>1</b> Peripheral<br><b>2</b> Portal<br><b>3</b> Pulmonary          |
| No change | <b>4</b> Venous           | <b>0</b> Open<br><b>3</b> Percutaneous   | <b>R</b> Saturation  | <b>1</b> Peripheral   |
| FY2021    | <b>4</b> Venous           | <b>4</b> Percutaneous<br>Endoscopic  | <b>B</b> Pressure  | <b>2</b> Portal   |
| No change | <b>4</b> Venous           | <b>X</b> External  | <b>5</b> Flow<br><b>B</b> Pressure<br><b>J</b> Pulse<br><b>R</b> Saturation  | <b>1</b> Peripheral   |
| No change | <b>5</b> Circulatory      | <b>X</b> External  | <b>L</b> Volume  | <b>Z</b> No Qualifier   |
| No change | <b>6</b> Lymphatic        | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>7</b> Via Natural or<br>Artificial Opening<br><b>8</b> Via Natural or<br>Artificial Opening<br>Endoscopic                       | <b>5</b> Flow<br><b>B</b> Pressure   | <b>Z</b> No Qualifier   |
| No change | <b>7</b> Visual           | <b>X</b> External  | <b>0</b> Acuity<br><b>7</b> Mobility<br><b>B</b> Pressure  | <b>Z</b> No Qualifier   |
| No change | <b>8</b> Olfactory        | <b>X</b> External  | <b>0</b> Acuity  | <b>Z</b> No Qualifier   |
| No change | <b>9</b> Respiratory      | <b>7</b> Via Natural or<br>Artificial Opening<br><b>8</b> Via Natural or<br>Artificial Opening<br>Endoscopic<br><b>X</b> External  | <b>1</b> Capacity<br><b>5</b> Flow<br><b>C</b> Rate<br><b>D</b> Resistance<br><b>L</b> Volume<br><b>M</b> Total Activity | <b>Z</b> No Qualifier   |
| No change | <b>B</b> Gastrointestinal | <b>7</b> Via Natural or<br>Artificial Opening<br><b>8</b> Via Natural or<br>Artificial Opening<br>Endoscopic   | <b>8</b> Motility<br><b>B</b> Pressure<br><b>G</b> Secretion   | <b>Z</b> No Qualifier   |
| No change | <b>C</b> Biliary          | <b>3</b> Percutaneous<br><b>4</b> Percutaneous<br>Endoscopic<br><b>7</b> Via Natural or<br>Artificial Opening<br><b>8</b> Via Natural or<br>Artificial Opening<br>Endoscopic | <b>5</b> Flow<br><b>B</b> Pressure   | <b>Z</b> No Qualifier   |
| No change | <b>D</b> Urinary          | <b>7</b> Via Natural or<br>Artificial Opening<br><b>8</b> Via Natural or<br>Artificial Opening<br>Endoscopic   | <b>3</b> Contractility<br><b>5</b> Flow<br><b>B</b> Pressure<br><b>D</b> Resistance<br><b>L</b> Volume                   | <b>Z</b> No Qualifier   |
| FY2021    | <b>F</b> Musculoskeletal  | <b>3</b> Percutaneous  | <b>3</b> Contractility   | <b>Z</b> No Qualifier   |

|           |  |  |  |                       |
|-----------|--|--|--|-----------------------|
| FY2021    | <b>F</b> Musculoskeletal                 | <b>3</b> Percutaneous  | <b>B</b> Pressure  | <b>E</b> Compartment  |
| FY2021    | <b>F</b> Musculoskeletal                 | <b>X</b> External  | <b>3</b> Contractility   | <b>Z</b> No Qualifier |
| No change | <b>H</b> Products of Conception, Cardiac | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic<br><b>X</b> External | <b>4</b> Electrical Activity<br><b>C</b> Rate<br><b>F</b> Rhythm<br><b>H</b> Sound | <b>Z</b> No Qualifier |
| No change | <b>J</b> Products of Conception, Nervous | <b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic<br><b>X</b> External | <b>2</b> Conductivity<br><b>4</b> Electrical Activity<br><b>B</b> Pressure         | <b>Z</b> No Qualifier |
| No change | <b>Z</b> None                            | <b>7</b> Via Natural or Artificial Opening   | <b>6</b> Metabolism<br><b>K</b> Temperature  | <b>Z</b> No Qualifier |
| No change | <b>Z</b> None                            | <b>X</b> External  | <b>6</b> Metabolism<br><b>K</b> Temperature<br><b>Q</b> Sleep                      | <b>Z</b> No Qualifier |

## 5A0

|           |  |   |                      |  |
|-----------|--|---|----------------------|--|
| No change | <b>Section 5</b> Extracorporeal or Systemic Assistance and Performance                                   |   |                      |  |
|           | <b>Body System A</b> Physiological Systems   |   |                      |  |
|           | <b>Operation 0</b> Assistance: Taking over a portion of a physiological function by extracorporeal means |   |                      |  |
| Heading   | <b>Body System</b>   | <b>Duration</b>   | <b>Function</b>      | <b>Qualifier</b>   |
| No change | <b>2</b> Cardiac   | <b>1</b> Intermittent<br><b>2</b> Continuous  | <b>1</b> Output      | <b>0</b> Balloon Pump<br><b>5</b> Pulsatile Compression<br><b>6</b> Other Pump<br><b>D</b> Impeller Pump   |
| No change | <b>5</b> Circulatory   | <b>1</b> Intermittent<br><b>2</b> Continuous  | <b>2</b> Oxygenation | <b>1</b> Hyperbaric<br><b>C</b> Supersaturated   |
| No change | <b>9</b> Respiratory   | <b>2</b> Continuous   | <b>0</b> Filtration  | <b>Z</b> No Qualifier  |
| FY2021    | <b>9</b> Respiratory   | <b>3</b> Less than 24 Consecutive Hours<br><b>4</b> 24-96 Consecutive Hours<br><b>5</b> Greater than 96 Consecutive Hours | <b>5</b> Ventilation | <b>7</b> Continuous Positive Airway Pressure<br><b>8</b> Intermittent Positive Airway Pressure<br><b>9</b> Continuous Negative Airway Pressure<br><b>A</b> High Nasal Flow/Velocity<br><b>B</b> Intermittent Negative Airway Pressure<br><b>Z</b> No Qualifier |

## 8E0

|           |  |   |   |   |
|-----------|--|---|---|---|
| No change | <b>Section</b> <b>8</b> Other Procedures<br><b>Body System</b> <b>E</b> Physiological Systems and Anatomical Regions<br><b>Operation</b> <b>0</b> Other Procedures: Methodologies which attempt to remediate or cure a disorder or disease |   |   |   |
|           | <b>Heading</b>   | <b>Body Region</b>  | <b>Approach</b>   | <b>Method</b>   |
|           | <b>Qualifier</b>   |   |   |   |
| No change | <b>1</b> Nervous System<br><b>U</b> Female Reproductive System   | <b>X</b> External   | <b>Y</b> Other Method   | <b>7</b> Examination  |
| FY2021    | <b>2</b> Circulatory System  | <b>3</b> Percutaneous<br><b>X</b> External  | <b>D</b> Near Infrared Spectroscopy   | <b>Z</b> No Qualifier   |
| No change | <b>9</b> Head and Neck Region  | <b>0</b> Open   | <b>C</b> Robotic Assisted Procedure   | <b>Z</b> No Qualifier   |
| No change | <b>9</b> Head and Neck Region  | <b>0</b> Open   | <b>E</b> Fluorescence Guided Procedure  | <b>M</b> Aminolevulinic Acid<br><b>Z</b> No Qualifier   |
| No change | <b>9</b> Head and Neck Region  | <b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic                  | <b>C</b> Robotic Assisted Procedure<br><b>E</b> Fluorescence Guided Procedure | <b>Z</b> No Qualifier   |
| No change | <b>9</b> Head and Neck Region  | <b>X</b> External   | <b>B</b> Computer Assisted Procedure  | <b>F</b> With Fluoroscopy<br><b>G</b> With Computerized Tomography<br><b>H</b> With Magnetic Resonance Imaging<br><b>Z</b> No Qualifier |
| No change | <b>9</b> Head and Neck Region  | <b>X</b> External   | <b>C</b> Robotic Assisted Procedure   | <b>Z</b> No Qualifier   |
| No change | <b>9</b> Head and Neck Region  | <b>X</b> External   | <b>Y</b> Other Method   | <b>8</b> Suture Removal   |
| No change | <b>H</b> Integumentary System and Breast   | <b>3</b> Percutaneous   | <b>0</b> Acupuncture  | <b>0</b> Anesthesia<br><b>Z</b> No Qualifier  |
| No change | <b>H</b> Integumentary System and Breast   | <b>X</b> External   | <b>6</b> Collection   | <b>2</b> Breast Milk  |
| No change | <b>H</b> Integumentary System and Breast   | <b>X</b> External   | <b>Y</b> Other Method   | <b>9</b> Piercing   |
| No change | <b>K</b> Musculoskeletal System  | <b>X</b> External   | <b>1</b> Therapeutic Massage  | <b>Z</b> No Qualifier   |
| No change | <b>K</b> Musculoskeletal System  | <b>X</b> External   | <b>Y</b> Other Method   | <b>7</b> Examination  |
| No change | <b>V</b> Male Reproductive System  | <b>X</b> External   | <b>1</b> Therapeutic Massage  | <b>C</b> Prostate<br><b>D</b> Rectum  |
| No change | <b>V</b> Male Reproductive System  | <b>X</b> External   | <b>6</b> Collection   | <b>3</b> Sperm  |
| No change | <b>W</b> Trunk Region  | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic<br><b>7</b> Via Natural or Artificial Opening<br><b>8</b> Via Natural or Artificial Opening Endoscopic | <b>C</b> Robotic Assisted Procedure<br><b>E</b> Fluorescence Guided Procedure | <b>Z</b> No Qualifier   |

|           |  |  |   |   |
|-----------|--|--|---|---|
| No change | <b>W</b> Trunk Region                                | <b>X</b> External  | <b>B</b> Computer Assisted Procedure  | <b>F</b> With Fluoroscopy<br><b>G</b> With Computerized Tomography<br><b>H</b> With Magnetic Resonance Imaging<br><b>Z</b> No Qualifier |
| No change | <b>W</b> Trunk Region                                | <b>X</b> External  | <b>C</b> Robotic Assisted Procedure   | <b>Z</b> No Qualifier   |
| No change | <b>W</b> Trunk Region                                | <b>X</b> External  | <b>Y</b> Other Method   | <b>8</b> Suture Removal   |
| No change | <b>X</b> Upper Extremity<br><b>Y</b> Lower Extremity | <b>0</b> Open<br><b>3</b> Percutaneous<br><b>4</b> Percutaneous Endoscopic | <b>C</b> Robotic Assisted Procedure<br><b>E</b> Fluorescence Guided Procedure | <b>Z</b> No Qualifier   |
| No change | <b>X</b> Upper Extremity<br><b>Y</b> Lower Extremity | <b>X</b> External  | <b>B</b> Computer Assisted Procedure  | <b>F</b> With Fluoroscopy<br><b>G</b> With Computerized Tomography<br><b>H</b> With Magnetic Resonance Imaging<br><b>Z</b> No Qualifier |
| No change | <b>X</b> Upper Extremity<br><b>Y</b> Lower Extremity | <b>X</b> External  | <b>C</b> Robotic Assisted Procedure   | <b>Z</b> No Qualifier   |
| No change | <b>X</b> Upper Extremity<br><b>Y</b> Lower Extremity | <b>X</b> External  | <b>Y</b> Other Method   | <b>8</b> Suture Removal   |
| No change | <b>Z</b> None  | <b>X</b> External  | <b>Y</b> Other Method   | <b>1</b> In Vitro Fertilization<br><b>4</b> Yoga Therapy<br><b>5</b> Meditation<br><b>6</b> Isolation                                   |



## BF5

|         |  |                            |   |  |
|---------|--|----------------------------|---|--|
| FY2021  | <i>Section</i> <b>B</b> Imaging  |                            |   |  |
|         | <i>Body System</i> <b>F</b> Hepatobiliary System and Pancreas  |                            |   |  |
|         | <i>Type</i> <b>5</b> Other Imaging: Other specified modality for visualizing a body part   |                            |   |  |
| Heading | <i>Body Part</i>   | <i>Contrast</i>            | <i>Qualifier</i>                                | <i>Qualifier</i>                         |
| FY2021  | <b>0</b> Bile Ducts<br><b>2</b> Gallbladder<br><b>3</b> Gallbladder and Bile Ducts<br><b>5</b> Liver<br><b>6</b> Liver and Spleen<br><b>7</b> Pancreas<br><b>C</b> Hepatobiliary System, All | <b>2</b> Fluorescing Agent | <b>0</b> Indocyanine Green Dye<br><b>Z</b> None | <b>0</b> Intraoperative<br><b>Z</b> None |

## BW5

|         |  |                 |                                     |                  |
|---------|--|-----------------|-------------------------------------|------------------|
| FY2021  | <i>Section</i> <b>B</b> Imaging  |                 |                                     |                  |
|         | <i>Body System</i> <b>W</b> Anatomical Regions   |                 |                                     |                  |
|         | <i>Type</i> <b>5</b> Other Imaging: Other specified modality for visualizing a body part         |                 |                                     |                  |
| Heading | <i>Body Part</i>   | <i>Contrast</i> | <i>Qualifier</i>                    | <i>Qualifier</i> |
| FY2021  | <b>2</b> Trunk<br><b>9</b> Head and Neck<br><b>C</b> Lower Extremity<br><b>J</b> Upper Extremity | <b>Z</b> None   | <b>1</b> Bacterial Autofluorescence | <b>Z</b> None    |

# D01

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy  |                               |  |   |
|           | <b>Body System</b> <b>0</b> Central and Peripheral Nervous System                          |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy   |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Brain<br><b>1</b> Brain Stem<br><b>6</b> Spinal Cord<br><b>7</b> Peripheral Nerve | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Brain<br><b>1</b> Brain Stem<br><b>6</b> Spinal Cord<br><b>7</b> Peripheral Nerve | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Brain<br><b>1</b> Brain Stem<br><b>6</b> Spinal Cord<br><b>7</b> Peripheral Nerve | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

## D0Y

|           |  |  |                |                  |
|-----------|--|--|----------------|------------------|
| No change | <i>Section</i> <b>D</b> Radiation Therapy  |  |                |                  |
|           | <i>Body System</i> <b>0</b> Central and Peripheral Nervous System                          |  |                |                  |
|           | <i>Modality</i> <b>Y</b> Other Radiation   |  |                |                  |
| Heading   | <i>Treatment Site</i>  | <i>Modality Qualifier</i>  | <i>Isotope</i> | <i>Qualifier</i> |
| FY2021    | <b>0</b> Brain<br><b>1</b> Brain Stem<br><b>6</b> Spinal Cord<br><b>7</b> Peripheral Nerve | <b>7</b> Contact Radiation<br><b>8</b> Hyperthermia<br><b>C</b> Intraoperative<br>Radiation Therapy<br>(IORT)<br><b>F</b> Plaque Radiation<br><b>K</b> Laser Interstitial<br>Thermal Therapy | <b>Z</b> None  | <b>Z</b> None    |

# D71

|           |   |                               |  |   |
|-----------|---|-------------------------------|--|---|
| No change | <b>Section D</b> Radiation Therapy  |                               |  |   |
|           | <b>Body System 7</b> Lymphatic and Hematologic System   |                               |  |   |
|           | <b>Modality 1</b> Brachytherapy   |                               |  |   |
| Heading   | <b>Treatment Site</b>   | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Bone Marrow<br><b>1</b> Thymus<br><b>2</b> Spleen<br><b>3</b> Lymphatics, Neck<br><b>4</b> Lymphatics, Axillary<br><b>5</b> Lymphatics, Thorax<br><b>6</b> Lymphatics, Abdomen<br><b>7</b> Lymphatics, Pelvis<br><b>8</b> Lymphatics, Inguinal | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Bone Marrow<br><b>1</b> Thymus<br><b>2</b> Spleen<br><b>3</b> Lymphatics, Neck<br><b>4</b> Lymphatics, Axillary<br><b>5</b> Lymphatics, Thorax<br><b>6</b> Lymphatics, Abdomen<br><b>7</b> Lymphatics, Pelvis<br><b>8</b> Lymphatics, Inguinal | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Bone Marrow<br><b>1</b> Thymus<br><b>2</b> Spleen<br><b>3</b> Lymphatics, Neck<br><b>4</b> Lymphatics, Axillary<br><b>5</b> Lymphatics, Thorax<br><b>6</b> Lymphatics, Abdomen<br><b>7</b> Lymphatics, Pelvis<br><b>8</b> Lymphatics, Inguinal | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

## D81

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy<br><b>Body System</b> <b>8</b> Eye<br><b>Modality</b> <b>1</b> Brachytherapy |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Eye   | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Eye   | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Eye   | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# D91

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section D</b> Radiation Therapy   |                               |  |   |
|           | <b>Body System 9</b> Ear, Nose, Mouth and Throat   |                               |  |   |
|           | <b>Modality 1</b> Brachytherapy  |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Ear<br><b>1</b> Nose<br><b>3</b> Hypopharynx<br><b>4</b> Mouth<br><b>5</b> Tongue<br><b>6</b> Salivary Glands<br><b>7</b> Sinuses<br><b>8</b> Hard Palate<br><b>9</b> Soft Palate<br><b>B</b> Larynx<br><b>D</b> Nasopharynx<br><b>F</b> Oropharynx | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Ear<br><b>1</b> Nose<br><b>3</b> Hypopharynx<br><b>4</b> Mouth<br><b>5</b> Tongue<br><b>6</b> Salivary Glands<br><b>7</b> Sinuses<br><b>8</b> Hard Palate<br><b>9</b> Soft Palate<br><b>B</b> Larynx<br><b>D</b> Nasopharynx<br><b>F</b> Oropharynx | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Ear<br><b>1</b> Nose<br><b>3</b> Hypopharynx<br><b>4</b> Mouth<br><b>5</b> Tongue<br><b>6</b> Salivary Glands<br><b>7</b> Sinuses<br><b>8</b> Hard Palate<br><b>9</b> Soft Palate<br><b>B</b> Larynx<br><b>D</b> Nasopharynx<br><b>F</b> Oropharynx | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DB1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy  |                               |  |   |
|           | <b>Body System</b> <b>B</b> Respiratory System   |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy   |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Trachea<br><b>1</b> Bronchus<br><b>2</b> Lung<br><b>5</b> Pleura<br><b>6</b> Mediastinum<br><b>7</b> Chest Wall<br><b>8</b> Diaphragm | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Trachea<br><b>1</b> Bronchus<br><b>2</b> Lung<br><b>5</b> Pleura<br><b>6</b> Mediastinum<br><b>7</b> Chest Wall<br><b>8</b> Diaphragm | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Trachea<br><b>1</b> Bronchus<br><b>2</b> Lung<br><b>5</b> Pleura<br><b>6</b> Mediastinum<br><b>7</b> Chest Wall<br><b>8</b> Diaphragm | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |



# DD1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy  |                               |  |   |
|           | <b>Body System</b> <b>D</b> Gastrointestinal System  |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy   |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Esophagus<br><b>1</b> Stomach<br><b>2</b> Duodenum<br><b>3</b> Jejunum<br><b>4</b> Ileum<br><b>5</b> Colon<br><b>7</b> Rectum | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Esophagus<br><b>1</b> Stomach<br><b>2</b> Duodenum<br><b>3</b> Jejunum<br><b>4</b> Ileum<br><b>5</b> Colon<br><b>7</b> Rectum | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Esophagus<br><b>1</b> Stomach<br><b>2</b> Duodenum<br><b>3</b> Jejunum<br><b>4</b> Ileum<br><b>5</b> Colon<br><b>7</b> Rectum | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DF1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy  |                               |  |   |
|           | <b>Body System</b> <b>F</b> Hepatobiliary System and Pancreas                      |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy   |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Liver<br><b>1</b> Gallbladder<br><b>2</b> Bile Ducts<br><b>3</b> Pancreas | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Liver<br><b>1</b> Gallbladder<br><b>2</b> Bile Ducts<br><b>3</b> Pancreas | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Liver<br><b>1</b> Gallbladder<br><b>2</b> Bile Ducts<br><b>3</b> Pancreas | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DG1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy  |                               |  |   |
|           | <b>Body System</b> <b>G</b> Endocrine System   |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy   |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Pituitary Gland<br><b>1</b> Pineal Body<br><b>2</b> Adrenal Glands<br><b>4</b> Parathyroid Glands<br><b>5</b> Thyroid | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Pituitary Gland<br><b>1</b> Pineal Body<br><b>2</b> Adrenal Glands<br><b>4</b> Parathyroid Glands<br><b>5</b> Thyroid | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Pituitary Gland<br><b>1</b> Pineal Body<br><b>2</b> Adrenal Glands<br><b>4</b> Parathyroid Glands<br><b>5</b> Thyroid | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DM1

|           |   |                               |  |   |
|-----------|---|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy<br><b>Body System</b> <b>M</b> Breast<br><b>Modality</b> <b>1</b> Brachytherapy |                               |  |   |
| Heading   | <b>Treatment Site</b>   | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Breast, Left<br><b>1</b> Breast, Right   | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Breast, Left<br><b>1</b> Breast, Right   | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Breast, Left<br><b>1</b> Breast, Right   | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DT1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy                                  |                               |  |   |
|           | <b>Body System</b> <b>T</b> Urinary System                                 |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy                                     |                               |  |   |
| Heading   | <b>Treatment Site</b>  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Kidney<br><b>1</b> Ureter<br><b>2</b> Bladder<br><b>3</b> Urethra | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Kidney<br><b>1</b> Ureter<br><b>2</b> Bladder<br><b>3</b> Urethra | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Kidney<br><b>1</b> Ureter<br><b>2</b> Bladder<br><b>3</b> Urethra | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DU1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy              |                               |  |   |
|           | <b>Body System</b> <b>U</b> Female Reproductive System |                               |  |   |
|           | <b>Modality</b> <b>1</b> Brachytherapy                 |                               |  |   |
| Heading   | <b>Treatment Site</b>                                  | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Ovary<br><b>1</b> Cervix<br><b>2</b> Uterus   | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Ovary<br><b>1</b> Cervix<br><b>2</b> Uterus   | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Ovary<br><b>1</b> Cervix<br><b>2</b> Uterus   | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DV1

|           |   |                               |  |   |
|-----------|---|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy<br><b>Body System</b> <b>V</b> Male Reproductive System<br><b>Modality</b> <b>1</b> Brachytherapy |                               |  |   |
| Heading   | <b>Treatment Site</b>   | <b>Modality Qualifier</b>     | <b>Isotope</b>   | <b>Qualifier</b>                                |
| No change | <b>0</b> Prostate<br><b>1</b> Testis  | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>0</b> Prostate<br><b>1</b> Testis  | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>0</b> Prostate<br><b>1</b> Testis  | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |

# DW1

|           |  |                               |  |   |
|-----------|--|-------------------------------|--|---|
| No change | <b>Section</b> <b>D</b> Radiation Therapy<br><b>Body System</b> <b>W</b> Anatomical Regions<br><b>Modality</b> <b>1</b> Brachytherapy  |                               |  |   |
|           | Heading  | <i>Treatment Site</i>         | <i>Modality Qualifier</i>  | <i>Isotope</i>                                  |
|           | <i>Qualifier</i>   |                               |  |   |
| No change | <b>0</b> Cranial Cavity<br><b>K</b> Upper Back<br><b>L</b> Lower Back<br><b>P</b> Gastrointestinal Tract<br><b>Q</b> Respiratory Tract<br><b>R</b> Genitourinary Tract<br><b>X</b> Upper Extremity<br><b>Y</b> Lower Extremity | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |
| No change | <b>1</b> Head and Neck<br><b>2</b> Chest<br><b>3</b> Abdomen<br><b>6</b> Pelvic Region   | <b>9</b> High Dose Rate (HDR) | <b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>B</b> Palladium 103 (Pd-103)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope | <b>Z</b> None                                   |
| FY2021    | <b>1</b> Head and Neck<br><b>2</b> Chest<br><b>3</b> Abdomen<br><b>6</b> Pelvic Region   | <b>B</b> Low Dose Rate (LDR)  | <b>6</b> Cesium 131 (Cs-131)<br><b>7</b> Cesium 137 (Cs-137)<br><b>8</b> Iridium 192 (Ir-192)<br><b>9</b> Iodine 125 (I-125)<br><b>C</b> Californium 252 (Cf-252)<br><b>Y</b> Other Isotope    | <b>Z</b> None                                   |
| No change | <b>1</b> Head and Neck<br><b>2</b> Chest<br><b>3</b> Abdomen<br><b>6</b> Pelvic Region   | <b>B</b> Low Dose Rate (LDR)  | <b>B</b> Palladium 103 (Pd-103)  | <b>1</b> Unidirectional Source<br><b>Z</b> None |



## X2A

|           |   |                       |  |                                 |
|-----------|---|-----------------------|--|---------------------------------|
| No change | <i>Section</i> <b>X</b> New Technology  |                       |  |                                 |
|           | <i>Body System</i> <b>2</b> Cardiovascular System   |                       |  |                                 |
|           | <i>Operation</i> <b>A</b> Assistance: Taking over a portion of a physiological function by extracorporeal means |                       |  |                                 |
| Heading   | <i>Body Part</i>  | <i>Approach</i>       | <i>Device / Substance / Technology</i>                                     | <i>Qualifier</i>                |
| No change | <b>5</b> Innominate Artery and Left Common Carotid Artery   | <b>3</b> Percutaneous | <b>1</b> Cerebral Embolic Filtration, Dual Filter                          | <b>2</b> New Technology Group 2 |
| No change | <b>6</b> Aortic Arch  | <b>3</b> Percutaneous | <b>2</b> Cerebral Embolic Filtration, Single Deflection Filter             | <b>5</b> New Technology Group 5 |
| FY2021    | <b>H</b> Common Carotid Artery, Right<br><b>J</b> Common Carotid Artery, Left                                   | <b>3</b> Percutaneous | <b>3</b> Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit | <b>6</b> New Technology Group 6 |

# XNU

|         |  |          |   |   |
|---------|--|----------|---|---|
| FY2021  | <i>Section</i>   | <b>X</b> | New Technology  |   |
|         | <i>Body System</i>                                     | <b>N</b> | Bones   |   |
|         | <i>Operation</i>                                       | <b>U</b> | Supplement: Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part |   |
| Heading | <i>Body Part</i>                                       |          | <i>Approach</i>   | <i>Device / Substance / Technology</i>                                |
| FY2021  | <b>0</b> Lumbar Vertebra<br><b>4</b> Thoracic Vertebra |          | <b>3</b> Percutaneous   | <b>5</b> Synthetic Substitute,<br>Mechanically Expandable<br>(Paired) |
|         |  |          |   | <b>6</b> New Technology Group 6                                       |

# XW0

|           |                              |                       |   |                                 |
|-----------|------------------------------|-----------------------|---|---------------------------------|
| No change | <i>Section</i>               | <b>X</b>              | New Technology  |                                 |
|           | <i>Body System</i>           | <b>W</b>              | Anatomical Regions  |                                 |
|           | <i>Operation</i>             | <b>0</b>              | Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products  |                                 |
| Heading   | <i>Body Part</i>             | <i>Approach</i>       | <i>Device / Substance / Technology</i>  | <i>Qualifier</i>                |
| FY2021    | <b>1</b> Subcutaneous Tissue | <b>3</b> Percutaneous | <b>F</b> Other New Technology Therapeutic Substance   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>1</b> Subcutaneous Tissue | <b>3</b> Percutaneous | <b>H</b> Other New Technology Monoclonal Antibody<br><b>K</b> Leronlimab Monoclonal Antibody<br><b>S</b> COVID-19 Vaccine Dose 1<br><b>T</b> COVID-19 Vaccine Dose 2<br><b>U</b> COVID-19 Vaccine | <b>6</b> New Technology Group 6 |
| No change | <b>1</b> Subcutaneous Tissue | <b>3</b> Percutaneous | <b>W</b> Caplacizumab   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>2</b> Muscle              | <b>3</b> Percutaneous | <b>S</b> COVID-19 Vaccine Dose 1<br><b>T</b> COVID-19 Vaccine Dose 2<br><b>U</b> COVID-19 Vaccine   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>0</b> Brexanolone  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>2</b> Ceftazidime-Avibactam Anti-infective   | <b>1</b> New Technology Group 1 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>2</b> Nerinitide   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>3</b> Idarucizumab, Dabigatran Reversal Agent  | <b>1</b> New Technology Group 1 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>3</b> Durvalumab Antineoplastic  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>4</b> Isavuconazole Anti-infective<br><b>5</b> Blinatumomab Antineoplastic Immunotherapy   | <b>1</b> New Technology Group 1 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>6</b> Lefamulin Anti-infective   | <b>6</b> New Technology Group 6 |
| No change | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>7</b> Coagulation Factor Xa, Inactivated<br><b>9</b> Defibrotide Sodium Anticoagulant  | <b>2</b> New Technology Group 2 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>9</b> Ceftolozane/Tazobactam Anti-infective  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>A</b> Bezlotoxumab Monoclonal Antibody   | <b>3</b> New Technology Group 3 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>A</b> Cefiderocol Anti-infective   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>B</b> Cytarabine and Daunorubicin Liposome Antineoplastic  | <b>3</b> New Technology Group 3 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>B</b> Omadacycline Anti-infective  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>C</b> Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy   | <b>3</b> New Technology Group 3 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>C</b> Eculizumab<br><b>D</b> Atezolizumab Antineoplastic   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>3</b> Peripheral Vein     | <b>3</b> Percutaneous | <b>E</b> Remdesivir Anti-infective  | <b>5</b> New Technology Group 5 |

|           |                   |                |   |                          |
|-----------|-------------------|----------------|---|--------------------------|
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | E Etesevimab Monoclonal Antibody  | 6 New Technology Group 6 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | F Other New Technology Therapeutic Substance  | 3 New Technology Group 3 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | F Other New Technology Therapeutic Substance  | 5 New Technology Group 5 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | F Bamlanivimab Monoclonal Antibody  | 6 New Technology Group 6 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | G Plazomicin Anti-infective   | 4 New Technology Group 4 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | G Sarilumab   | 5 New Technology Group 5 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | G REGN-COV2 Monoclonal Antibody   | 6 New Technology Group 6 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | H Synthetic Human Angiotensin II  | 4 New Technology Group 4 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | H Tocilizumab   | 5 New Technology Group 5 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | H Other New Technology Monoclonal Antibody  | 6 New Technology Group 6 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | K Fosfomycin Anti-infective   | 5 New Technology Group 5 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | L CD24Fc Immunomodulator  | 6 New Technology Group 6 |
| FY2021    | 3 Peripheral Vein | 3 Percutaneous | N Meropenem-vaborbactam Anti-infective<br>Q Tagraxofusp-erzs Antineoplastic<br>S Iobenguane I-131 Antineoplastic<br>U Imipenem-cilastatin-relebactam Anti-infective<br>W Caplacizumab | 5 New Technology Group 5 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | O Brexanolone   | 6 New Technology Group 6 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 2 Ceftazidime-Avibactam Anti-infective  | 1 New Technology Group 1 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 2 Nerinitide  | 6 New Technology Group 6 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 3 Idarucizumab, Dabigatran Reversal Agent   | 1 New Technology Group 1 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 3 Durvalumab Antineoplastic   | 6 New Technology Group 6 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 4 Isavuconazole Anti-infective<br>5 Blinatumomab Antineoplastic Immunotherapy   | 1 New Technology Group 1 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 6 Lefamulin Anti-infective  | 6 New Technology Group 6 |
| No change | 4 Central Vein    | 3 Percutaneous | 7 Coagulation Factor Xa, Inactivated<br>9 Defibrotide Sodium Anticoagulant  | 2 New Technology Group 2 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | 9 Ceftolozane/Tazobactam Anti-infective   | 6 New Technology Group 6 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | A Bezlotoxumab Monoclonal Antibody  | 3 New Technology Group 3 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | A Cefiderocol Anti-infective  | 6 New Technology Group 6 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | B Cytarabine and Daunorubicin Liposome Antineoplastic   | 3 New Technology Group 3 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | B Omadacycline Anti-infective   | 6 New Technology Group 6 |
| FY2021    | 4 Central Vein    | 3 Percutaneous | C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy  | 3 New Technology Group 3 |

|           |  |   |  |                                 |
|-----------|--|---|--|---------------------------------|
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>C</b> Eculizumab<br><b>D</b> Atezolizumab<br>Antineoplastic   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>E</b> Remdesivir Anti-infective   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>E</b> Etesevimab Monoclonal Antibody  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>F</b> Other New Technology Therapeutic Substance  | <b>3</b> New Technology Group 3 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>F</b> Other New Technology Therapeutic Substance  | <b>5</b> New Technology Group 5 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>F</b> Bamlanivimab Monoclonal Antibody  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>G</b> Plazomicin Anti-infective   | <b>4</b> New Technology Group 4 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>G</b> Sarilumab   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>G</b> REGN-COV2 Monoclonal Antibody   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>H</b> Synthetic Human Angiotensin II  | <b>4</b> New Technology Group 4 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>H</b> Tocilizumab   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>H</b> Other New Technology Monoclonal Antibody  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>K</b> Fosfomycin Anti-infective   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>L</b> CD24Fc Immunomodulator  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>4</b> Central Vein                  | <b>3</b> Percutaneous                                 | <b>N</b> Meropenem-vaborbactam Anti-infective<br><b>Q</b> Tagraxofusp-erzs Antineoplastic<br><b>S</b> Iobenguane I-131 Antineoplastic<br><b>U</b> Imipenem-cilastatin-relebactam Anti-infective<br><b>W</b> Caplacizumab | <b>5</b> New Technology Group 5 |
| FY2021    | <b>9</b> Nose                          | <b>7</b> Via Natural or Artificial Opening            | <b>M</b> Esketamine Hydrochloride  | <b>5</b> New Technology Group 5 |
| FY2021    | <b>D</b> Mouth and Pharynx             | <b>X</b> External                                     | <b>6</b> Lefamulin Anti-infective  | <b>6</b> New Technology Group 6 |
| No change | <b>D</b> Mouth and Pharynx             | <b>X</b> External                                     | <b>8</b> Uridine Triacetate  | <b>2</b> New Technology Group 2 |
| FY2021    | <b>D</b> Mouth and Pharynx             | <b>X</b> External                                     | <b>F</b> Other New Technology Therapeutic Substance<br><b>J</b> Apalutamide Antineoplastic<br><b>L</b> Erdafitinib Antineoplastic  | <b>5</b> New Technology Group 5 |
| FY2021    | <b>D</b> Mouth and Pharynx             | <b>X</b> External                                     | <b>M</b> Baricitinib   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>D</b> Mouth and Pharynx             | <b>X</b> External                                     | <b>R</b> Venetoclax Antineoplastic<br><b>T</b> Ruxolitinib<br><b>V</b> Gilteritinib Antineoplastic   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>G</b> Upper GI<br><b>H</b> Lower GI | <b>7</b> Via Natural or Artificial Opening            | <b>M</b> Baricitinib   | <b>6</b> New Technology Group 6 |
| FY2021    | <b>G</b> Upper GI<br><b>H</b> Lower GI | <b>8</b> Via Natural or Artificial Opening Endoscopic | <b>8</b> Mineral-based Topical Hemostatic Agent  | <b>6</b> New Technology Group 6 |
| FY2021    | <b>Q</b> Cranial Cavity and Brain      | <b>3</b> Percutaneous                                 | <b>1</b> Eladocagene exuparvovec   | <b>6</b> New Technology Group 6 |

# XW1

|         |   |                       |  |                                 |
|---------|---|-----------------------|--|---------------------------------|
| FY2021  | <i>Section</i> <b>X</b> New Technology                                    |                       |  |                                 |
|         | <i>Body System</i> <b>W</b> Anatomical Regions                            |                       |  |                                 |
|         | <i>Operation</i> <b>1</b> Transfusion: Putting in blood or blood products |                       |  |                                 |
| Heading | <i>Body Part</i>  | <i>Approach</i>       | <i>Device / Substance / Technology</i> | <i>Qualifier</i>                |
| FY2021  | <b>3</b> Peripheral Vein  | <b>3</b> Percutaneous | <b>2</b> Plasma, Convalescent          | <b>5</b> New Technology Group 5 |
|         | <b>4</b> Central Vein   |                       | (Nonautologous)                        |                                 |

## XW2

|         |   |                       |   |                                 |
|---------|---|-----------------------|---|---------------------------------|
| FY2021  | <b>Section</b> <b>X</b> New Technology                                    |                       |   |                                 |
|         | <b>Body System</b> <b>W</b> Anatomical Regions                            |                       |   |                                 |
|         | <b>Operation</b> <b>2</b> Transfusion: Putting in blood or blood products |                       |   |                                 |
| Heading | <b>Body Part</b>  | <b>Approach</b>       | <b>Device / Substance / Technology</b>  | <b>Qualifier</b>                |
| FY2021  | <b>3</b> Peripheral Vein<br><b>4</b> Central Vein                         | <b>3</b> Percutaneous | <b>4</b> Brexucabtagene Autoleucel Immunotherapy<br><b>7</b> Lisocabtagene Maraleucel Immunotherapy | <b>6</b> New Technology Group 6 |

# XXE

|           |                      |                   |   |                                 |
|-----------|----------------------|-------------------|---|---------------------------------|
| No change | <i>Section</i>       | <b>X</b>          | New Technology  |                                 |
|           | <i>Body System</i>   | <b>X</b>          | Physiological Systems   |                                 |
|           | <i>Operation</i>     | <b>E</b>          | Measurement: Determining the level of a physiological or physical function at a point in time                                       |                                 |
| Heading   | <i>Body Part</i>     | <i>Approach</i>   | <i>Device / Substance / Technology</i>  | <i>Qualifier</i>                |
| No change | <b>5</b> Circulatory | <b>X</b> External | <b>M</b> Infection, Whole Blood Nucleic Acid-base Microbial Detection   | <b>5</b> New Technology Group 5 |
| FY2021    | <b>5</b> Circulatory | <b>X</b> External | <b>N</b> Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility | <b>6</b> New Technology Group 6 |
| FY2021    | <b>B</b> Respiratory | <b>X</b> External | <b>Q</b> Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection   | <b>6</b> New Technology Group 6 |